CD274 and non-small cell lung carcinoma: Moreover, a multicenter retrospective study recently conducted by Aguilar EJ showed that the treatment effect of the first-line treatment pembrolizumab was significantly better in NSCLC patients with PD-L1 expression ≥ 50% than in those with PD-L1 expression ≥ 90% (32).